Safety & Pharmacokinetics Study Of Azacitidine (SC And Oral) In Subjects With MDS, CMML, AML, Lymphoma And Multiple Myeloma

Inclusion Criteria:

18 years or older
Diagnosis of MDS or CMML
Diagnosis of AML, Multiple myeloma, Hodgkin's or Non-Hodgkin's lymphoma for whom standard curative or palliative measures do not exist or are no longer effective
ECOG Performance Status 0-2
Use of acceptable birth control
Standard safety inclusion for serum creatinine, AST, ALT, bilirubin
Serum bicarbonate greater than or equal to 20 mEq/L
Platelet count greater than or equal to 25,000/uL
Hemoglobin greater than or equal to 500/uL
Signed informed consent

Exclusion Criteria:

Diagnosis of acute promyelocytic leukemia
Treatment with demethylating agents within 21 days prior to Cycle 1, Day 1
Treatment with any anticancer therapy (standard or investigational) within 21 days prior to Cycle 1, Day 1 or ongoing adverse events from previous treatment
Hypersensitivity to azacitidine or mannitol
Active, uncontrolled infection
Presence of GI disease, malignant tumors or other conditions known to interfere with ADME
Known or active HIV, viral hepatitis B or C
Breastfeeding or pregnant females
Current or uncontrolled cardiac disease